[1]Alpers CE, Hudkins KL.Mouse models of diabetic nephropathy.Curr Opin Nephrol Hypertens. 2011;20(3): 278-284.
[2]Bang OY, Lee JS, Lee PH,et al.Autologous mesenchymal stem cell transplantation in stroke patients.Ann Neurol. 2005;57(6):874-882.
[3]Blázquez-Medela AM, López-Novoa JM, Martínez-Salgado C.Mechanisms involved in the genesis of diabetic nephropathy.Curr Diabetes Rev. 2010;6(2):68-87.
[4]Breyer MD, Böttinger E, Brosius FC 3rd, et al. Mouse models of diabetic nephropathy.J Am Soc Nephrol. 2005;16(1):27-45.
[5]Brownlee M.Biochemistry and molecular cell biology of diabetic complications.Nature. 2001;414(6865):813-820.
[6]Caplan AI, Dennis JE.Mesenchymal stem cells as trophic mediators.J Cell Biochem. 2006;98(5):1076-1084.
[7]Carvalho AB, Quintanilha LF, Dias JV,et al. Bone marrow multipotent mesenchymal stromal cells do not reduce fibrosis or improve function in a rat model of severe chronic liver injury.Stem Cells. 2008;26(5):1307-1314.
[8]Chawla T, Sharma D, Singh A.Role of the renin angiotensin system in diabetic nephropathy.World J Diabetes. 2010; 1(5):141-145.
[9]Choudhury D, Tuncel M, Levi M.Diabetic nephropathy -- a multifaceted target of new therapies.Discov Med. 2010; 10(54):406-415.
[10]Chow FY, Nikolic-Paterson DJ, Ozols E,et al.Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice.Kidney Int. 2006;69(1):73-80.
[11]Cnop M, Welsh N, Jonas JC,et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities.Diabetes. 2005;54 Suppl 2: S97-107.
[12]Conget P, Rodriguez F, Kramer S,et al.Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa.Cytotherapy. 2010;12(3): 429-431.
[13]Cornacchia F, Fornoni A, Plati AR,et al.Glomerulosclerosis is transmitted by bone marrow-derived mesangial cell progenitors. J Clin Invest. 2001;108(11):1649-1656.
[14]Dalla Vestra M, Mussap M, Gallina P,et al.Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes.J Am Soc Nephrol. 2005;16 Suppl 1: S78-82.
[15]di Bonzo LV, Ferrero I, Cravanzola C,et al.Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential.Gut. 2008; 57(2):223-231.
[16]DiPetrillo K, Coutermarsh B, Soucy N,et al.Tumor necrosis factor induces sodium retention in diabetic rats through sequential effects on distal tubule cells.Kidney Int. 2004; 65(5):1676-1683.
[17]Dominici M, Le Blanc K, Mueller I,et al.Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.
[18]Evans JL, Goldfine ID, Maddux BA,et al.Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes.Endocr Rev. 2002;23(5):599-622.
[19]Ezquer F, Ezquer M, Simon V,et al.Endovenous administration of bone-marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice.Biol Blood Marrow Transplant. 2009;15(11):1354-1365.
[20]Ezquer FE, Ezquer ME, Parrau DB,et al.Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice.Biol Blood Marrow Transplant. 2008;14(6):631- 640.
[21]Ezquer M, Ezquer F, Ricca M,et al.Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome.J Hepatol. 2011;55(5):1112-1120.
[22]Fioretto P, Mauer M.Reversal of diabetic nephropathy: lessons from pancreas transplantation.J Nephrol. 2012; 25(1): 13-18.
[23]Fouillard L, Bensidhoum M, Bories D,et al.Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma. Leukemia. 2003;17(2):474-476.
[24]Fujita H, Fujishima H, Chida S,et al.Reduction of renal superoxide dismutase in progressive diabetic nephropathy.J Am Soc Nephrol. 2009;20(6):1303-1313.
[25]Galkina E, Ley K.Leukocyte recruitment and vascular injury in diabetic nephropathy.J Am Soc Nephrol. 2006;17(2):368- 377.
[26]Giordano A1, Galderisi U, Marino IR.From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells.J Cell Physiol. 2007;211(1): 27-35.
[27]Gnecchi M, He H, Liang OD,et al.Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells.Nat Med. 2005;11(4):367-368.
[28]Grimm PC, Nickerson P, Jeffery J,et al. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection.N Engl J Med. 2001;345(2): 93-97.
[29]Gupta S, Verfaillie C, Chmielewski D,et al.A role for extrarenal cells in the regeneration following acute renal failure.Kidney Int. 2002;62(4):1285-1290.
[30]Higashiyama R, Inagaki Y, Hong YY,et al.Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice.Hepatology. 2007;45(1):213-222.
[31]Imasawa T, Utsunomiya Y, Kawamura T,et al.The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells.J Am Soc Nephrol. 2001;12(7):1401-1409.
[32]Imberti B, Morigi M, Tomasoni S,et al. Insulin-like growth factor-1 sustains stem cell mediated renal repair.J Am Soc Nephrol. 2007;18(11):2921-2928.
[33]Inada A, Nagai K, Arai H,et al.Establishment of a diabetic mouse model with progressive diabetic nephropathy.Am J Pathol. 2005;167(2):327-336.
[34]Ishikura H, Takahashi C, Kanagawa K, et al.Cytokine regulation of ICAM-1 expression on human renal tubular epithelial cells in vitro.Transplantation. 1991;51(6):1272-1275.
[35]Ito T, Suzuki A, Imai E,et al.Bone marrow is a reservoir of repopulating mesangial cells during glomerular remodeling.J Am Soc Nephrol. 2001;12(12):2625-2635.
[36]Jerums G, Panagiotopoulos S, Premaratne E,et al.Lowering of proteinuria in response to antihypertensive therapy predicts improved renal function in late but not in early diabetic nephropathy: a pooled analysis.Am J Nephrol. 2008;28(4): 614-627.
[37]Jiang XX, Zhang Y, Liu B,et al.Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells.Blood. 2005;105(10):4120-4126.
[38]Kale S, Karihaloo A, Clark PR,et al.Bone marrow stem cells contribute to repair of the ischemically injured renal tubule.J Clin Invest. 2003;112(1):42-49.
[39]Kinnaird T, Stabile E, Burnett MS,et al.Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms.Circ Res. 2004;94(5):678-685.
[40]Kinnaird T, Stabile E, Burnett MS,et al.Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms.Circulation. 2004;109(12): 1543-1549.
[41]Koç ON, Day J, Nieder M,et al.Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH).Bone Marrow Transplant. 2002;30(4):215-222.
[42]Krause D, Cantley LG.Bone marrow plasticity revisited: protection or differentiation in the kidney tubule. J Clin Invest. 2005;115(7):1705-1708.
[43]Lange C, Tögel F, Ittrich H,et al.Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion- induced acute renal failure in rats.Kidney Int. 2005;68(4): 1613-1617.
[44]Le Blanc K, Götherström C, Ringdén O,et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta.Transplantation. 2005;79(11):1607-1614.
[45]Le Blanc K, Rasmusson I, Sundberg B,et al.Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.Lancet. 2004; 363 (9419): 1439-1441.
[46]Lee RH, Seo MJ, Reger RL,et al.Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice.Proc Natl Acad Sci U S A. 2006;103(46):17438-17443.
[47]Maccario R, Podestà M, Moretta A,et al.Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype.Haematologica. 2005; 90(4):516-525.
[48]Maric C, Hall JE.Obesity, metabolic syndrome and diabetic nephropathy.Contrib Nephrol. 2011;170:28-35.
[49]Matsui H, Suzuki M, Tsukuda R,et al.Expression of ICAM-1 on glomeruli is associated with progression of diabetic nephropathy in a genetically obese diabetic rat, Wistar fatty.Diabetes Res Clin Pract. 1996;32(1-2):1-9.
[50]McCarthy ET, Sharma R, Sharma M,et al.TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide.J Am Soc Nephrol. 1998;9(3):433-438.
[51]McCrary EB.The road to renal failure: an overview of diabetic nephropathy.Adv Nurse Pract. 2008;16(7):61-63.
[52]Mertes H, Pennings G.Cross-border research on human embryonic stem cells: legal and ethical considerations.Stem Cell Rev. 2009;5(1):10-17.
[53]Minguell JJ, Erices A, Conget P.Mesenchymal stem cells.Exp Biol Med (Maywood). 2001;226(6):507-520.
[54]Garg AX, Kiberd BA, Clark WF,et al.Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III.Kidney Int. 2002;61(6):2165-2175.
[55]Coresh J, Selvin E, Stevens LA,et al.Prevalence of chronic kidney disease in the United States.JAMA. 2007;298(17): 2038-2047.
[56]Chadban SJ, Briganti EM, Kerr PG,et al.Prevalence of kidney damage in Australian adults: The AusDiab kidney study.J Am Soc Nephrol. 2003;14(7 Suppl 2):S131-138.
[57]Iseki K, Kohagura K, Sakima A,et al.Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003).Hypertens Res. 2007;30(1): 55-62.
[58]Xue JL, Ma JZ, Louis TA,et al.Forecast of the number of patients with end-stage renal disease in the United States to the year 2010.J Am Soc Nephrol. 2001;12(12):2753-2758.
[59]Schieppati A, Remuzzi G.Chronic renal diseases as a public health problem: epidemiology, social, and economic implications.Kidney Int Suppl. 2005;(98):S7-S10.
[60]National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266. |